Display Settings:


Send to:

Choose Destination
Eur J Pediatr. 2011 May;170(5):625-31. doi: 10.1007/s00431-010-1335-z. Epub 2010 Oct 23.

Neonatal severe hyperparathyroidism: further clinical and molecular delineation.

Author information

  • 1Section of Pediatric Endocrinology, Department of Pediatrics, Hamad Medical Corporation, Doha, Qatar.


We report a newborn female from a consanguineous Sri Lankan family with clinical and biochemical features of neonatal severe hyperparathyroidism (NSHPT). Mutation screening of the calcium-sensing receptor (CASR) gene in genomic DNA revealed a homozygous truncating mutation (c.679C>T, predicting p.R227X), confirming the clinical diagnosis. Other mutations at the R227 position are reported to cause varying degrees of hypercalcemia and hyperparathyroidism, but this nonsense variant is novel and expected to induce unremitting hyperparathyroidism from birth onward. In our patient with NSHPT, early bisphosphonate therapy was crucial in counteracting the marked hypercalcemia and allowed for safe surgical intervention ("total" parathyroidectomy, "thymectomy and hemithyroidectomy") at 3 months of age. Conclusion: This report highlights the continuing challenges in diagnosis and management of this life-threatening condition.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk